Physician

Scott C Ulmer, M.D.

According to 2025 Medicare claims, Scott Ulmer, M.D. (NPI: 1063441772) practices hematology/oncology in the San Antonio-New Braunfels, TX market, with the plurality of this provider's patient population coming from Bexar, TX. This provider's primary affiliated billing organization is SOUTH TEXAS ONCOLOGY AND HEMATOLOGY, PLLC (NPI: 1770664542; TIN: 742915297) and primary practice location at 78258-3989.

Ulmer's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 519 traditional Medicare patients, billed 205,992 HCPCS/CPT codes, and received $4,024,001 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 1,224 prescription claims across 195 beneficiaries totaling $2,249,043 in drug costs, led by Pomalyst (Pomalidomide). 2023 DME data shows 52 claims. Open Payments data shows 49 records totaling $5,813. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,066,387 to $4,024,001. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,101,516 to $2,249,043. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	510	186,711	$2,066,387
2016	543	211,796	$3,284,312
2017	531	159,056	$3,001,928
2018	545	180,091	$2,832,743
2019	552	164,058	$3,090,737
2020	474	168,600	$4,044,906
2021	542	197,191	$4,881,151
2022	526	191,901	$4,127,751
2023	541	216,132	$4,087,488
2024	519	205,992	$4,024,001

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	120	1,126	$1,101,516
2016	126	1,085	$743,800
2017	151	1,246	$1,653,419
2018	153	1,187	$1,711,045
2019	173	1,346	$2,332,112
2020	175	1,309	$2,384,351
2021	170	1,477	$3,860,040
2022	198	1,307	$2,305,313
2023	207	1,361	$2,339,562
2024	195	1,224	$2,249,043

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	14	115	$47,713
2016	N/R	32	$13,655
2017	N/R	69	$19,842
2018	N/R	39	$6,655
2019	N/R	27	$2,408
2020	N/R	51	$1,934
2021	N/R	22	$1,484
2022	N/R	30	$801
2023	N/R	52	$7,512
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	372	804	$65
80053	Blood test, comprehensive group of blood chemicals	419	1,588	$10
36415	Insertion of needle into vein for collection of blood sample	442	1,668	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	420	1,641	$8
83615	Lactate dehydrogenase (enzyme) level	288	792	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	22	511	$294,582
Alecensa	Alectinib Hcl	14	420	$258,216
Venclexta	Venetoclax	20	596	$224,273
Imbruvica	Ibrutinib	17	500	$221,739
Jakafi	Ruxolitinib Phosphate	13	390	$217,242

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	49	$5,813	Karyopharm Therapeutics Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Scott C. Ulmer, M.D.?

Tedicare shows public-source Medicare data for Scott C. Ulmer, M.D. (NPI 1063441772), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Scott C. Ulmer, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Scott C. Ulmer, M.D.?

Scott C. Ulmer, M.D. is linked to SOUTH TEXAS ONCOLOGY AND HEMATOLOGY, PLLC (billing NPI 1770664542) in the available physician profile data.

Does Scott C. Ulmer, M.D. have Open Payments data?

Scott C. Ulmer, M.D. has 49 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.